Lung Cancer Trials

Phase 3 Clinical Trial in Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

ENSPIRIT is a company-sponsored Phase 3 trial evaluating the potential of custirsen to improve survival outcomes in patients with advanced or metastatic NSCLC who have progressed after initial chemotherapy treatment has failed. Patients will be randomly selected to receive a second-line standard of care, docetaxel treatment, with or without custirsen therapy. The trial will enroll approximately 1,100 patients with advanced or metastatic NSCLC and is being conducted internationally.

Learn More about the ENSPIRIT trial.

Phase 2 Clinical Trial in Advanced Non-Small Cell Lung Cancer (NSCLC)

Spruce™ is an investigator-sponsored, randomized, placebo-controlled Phase 2 trial evaluating OGX-427 in combination with carboplatin and pemetrexed in patients with previously untreated, advanced, non-squamous NSCLC. Spruce is designed to evaluate the potential benefit of adding OGX-427 to carboplatin and pemetrexed therapy by measuring the treatments’ ability to extend time without disease progression. The trial is sponsored by the Sarah Cannon Research Institute (SCRI).

Learn More about the Spruce Trial.

Phase 2 Clinical Trial in Advanced Non-Small Cell Lung Cancer (NSCLC)

Cedar™ is an investigator-sponsored, randomized, open-label Phase 2 trial evaluating OGX-427 in combination with gemcitabine and carboplatin in patients with previously untreated, advanced, squamous NSCLC. Cedar is designed to evaluate the potential benefit of adding OGX-427 to gemcitabine and carboplatin therapy by measuring the treatments’ ability to extend time without disease progression, and other endpoints such as survival, health related quality of life and tumor response rates. This trial is being conducted by the UK National Cancer Research Network and the UK Experimental Cancer Medicine Network and will involve 35 centers in the United Kingdom.